MCL1 and neoplasm: Thus, while treatment with MRX-2843 combined with venetoclax or navitoclax provided robust anti-tumor activity in the studies reported here, the combined inhibition of BCL-XL, MCL1 and MERTK may provide even further improvement in therapeutic efficacy against EWS.